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Abstract: Diabetes mellitus is characterized by a lack of insulin causing elevated blood glucose, 
often with associated insulin resistance. Over time, especially in genetically susceptible individu-
als, such chronic hyperglycemia can cause tissue injury. One pathological response to tissue 
injury is the development of ﬁ  brosis, which involves predominant extracellular matrix (ECM) 
accumulation. The main factors that regulate ECM in diabetes are thought to be pro-sclerotic 
cytokines and protease/anti-protease systems. This review will examine the key markers and 
regulators of tissue ﬁ  brosis in diabetes and whether their levels in biological ﬂ  uids may have 
clinical utility.
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Introduction
Fibrosis is characterized by extracellular matrix (ECM) accumulation and often by a 
change in the quality of the ECM, as well as angiogenesis. It is a common pathological 
response to tissue insults such as hyperglycemia, dyslipidemia, and hypertension. This 
review will examine the extent and type of tissue ﬁ  brosis that occurs in experimental 
and human diabetes, with an emphasis on potential circulating and urinary predic-
tors and markers of ﬁ  brosis in human diabetes. While the pathogenesis and nature 
of end-organ complications in type 1 and type 2 diabetes are similar, especially in 
glucose-dependent aspects of microvascular disease, where possible throughout the 
text the type of diabetes is referenced.
Fibrosis in tissues affected by diabetic 
complications
Microvessels
Long-standing diabetes leads to both structural and functional anomalies in the vasculature 
(Zimmet 2000; Khan et al 2003) which characterize micro- and macrovascular diabetic 
complications: retinopathy, nephropathy, cardiomyopathy, peripheral vascular disease, 
cerebrovascular disorders, and atherosclerosis. Firstly described by Siperstein and 
colleagues (1968), extracellular matrix (ECM) alterations and basement membrane 
(BM) thickening have been documented as structural hallmarks in all target organs of 
diabetic complications (Brownlee et al 1979; Tsilibary 2003). The morphological and 
biochemical disturbances of the ECM are directly related to a loss of function in target 
organs (Farquhar et al 1972; Scheinman et al 1974; Ikeda et al 1991; Makino et al 1993). 
ECM comprises an insoluble network of collagens, elastins, structural glycoproteins, 
proteoglycans-hyaluronans and integrins, which provide not only mechanical support 
for the cells, but also mediate complex interactions between the cells or between cells 
and the ECM of vascular tissues (Hayden et al 2005). EC matrices differ qualitatively 
and quantitatively from tissue to tissue and within various organs.Vascular Health and Risk Management 2008:4(3) 576
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Diabetic retinopathy
Expansion of ECM that occurs in diabetic complications can 
be due to increased synthesis of matrix proteins and/or an 
inhibition of ECM degradation. With respect to the increased 
synthesis of matrix, proteins that are normally present in these 
structures or proteins that are not present in normal tissue, 
or both, may be induced. Thus, collagen types I and IV as 
well as laminin and ﬁ  bronectin are normal constituents of 
normal retinal vessels from large thick-walled vessels down 
to microvessels less than 10 microns in diameter, whilst 
types III and V collagen were seen to stain primarily the 
walls of the larger vessels. A preclinical hallmark of early 
diabetic retinopathy (DR) is the thickening of the capillary 
basement membrane (BM) resulting from increased produc-
tion and/or decreased breakdown of collagen IV, laminin, 
ﬁ  bronectin, and other proteins (Roy et al 1990; Ljubimov 
et al 1996; Spirin et al 1999; Lorenzi et al 2001). In prolifera-
tive diabetic retinopathy (PDR), the BM of the new vessels 
and the epiretinal membranes show signiﬁ  cantly increased 
amounts of types VI, VIII, XII, and XIV collagen, as well 
as perlecan, bamacan (Ljubimov et al 1996), ﬁ  bronectin, 
tenascin (Ioachim et al 2005), and vimentin (Hosoda et al 
1993). While not present in normal retina (Jerdan et al 
1986), type II collagen was found in epiretinal membranes 
(ERM) (Hosoda et al 1993). A positive relationship was 
found between ﬁ  bronectin expression and ERM proliferative 
activity (Ioachim et al 2005). Downregulation of ﬁ  bronectin 
synthesis could partially prevent retinal BM thickening along 
with a reduction of pericyte loss and acellular capillaries in 
animal model (Roy et al 2003).
Diabetic renal disease
Type IV collagen collagen, ﬁ  bronectin and laminin, which 
are normal constituents of the mesangium and glomerular 
basement membrane (GBM), are increased in diabetic kidney 
disease (Kim et al 1991; Makino et al 1993; Kiryu et al 1994; 
Zhu et al 1994; Yagame et al 1995; Razzaque et al 1997; 
Moriya et al 2001). Accelerated matrix deposition (type IV 
collagen) can be present even in early stages of diabetic renal 
disease (microalbuminuria stages) in experimental models 
(Liu Y et al 2007). In diabetic diffuse glomerulosclerosis 
deposition of collagen IV, V, laminin, and ﬁ  bronectin is 
increased in the mesangial matrix and glomerular basement 
membranes (Nerlich et al 1991; Tsilibary 2003), whilst in 
nodular glomerulosclerosis normal BM components are 
decreased or absent (Olgemoller et al 1993). Expressed only 
under pathological conditions, type I and III collagen appears 
in the late stages of glomerulosclerosis (Glick et al 1992; 
Makino et al 1994; Razzaque et al 1994; Makino et al 1995; 
Stokes et al 2000; Schaefer et al 2001), and are associated 
with the development of Kimmelstiel-Wilson nodules rather 
than with the diffuse expansion of the mesangial matrix, 
which occurs in the early and moderately advanced stages 
of the disease. Decreased levels of proteoglycans (heparin 
sulphate, perlecan) found in diabetic kidney in the mesangial 
matrix, GBM, the endothelial and epithelial BM, and renal 
tubular cells have also been assigned a role in the develop-
ment of diabetic micro- and macroalbuminuria (Schaefer et al 
2001). Interestingly, a substantial subset of type 2 diabetic 
patients, despite the presence of microalbuminuria or pro-
teinuria, have normal glomerular structure with or without 
tubulointerstitial and/or arteriolar abnormalities (Fioretto 
et al 2007).
Diabetic cardiomyopathy
Both types I and III collagen are present in normal and 
diseased myocardial tissue. Type I collagen is predominant 
in the myocardium, but type III is more speciﬁ  c to cardiac 
tissue (Bishop et al 1995; Zannad et al 2000; D’Armiento 
2002). Myocardial biopsies from diabetic subjects revealed a 
signiﬁ  cantly higher proportion of type III collagen compared 
with their nondiabetic counterparts, while the proportion of 
collagen type I did not differ between the groups (Shimizu 
et al 1993). Responsible for the increased left ventricle (LV) 
mass (van Hoeven et al 1990), diffuse myocardial ﬁ  brosis 
has a distribution in both interstitium and perivascular sites 
(Regan et al 1977; Nunoda et al 1985; Genda et al 1986; 
Das et al 1987; van Hoeven and Factor 1990). Extensive 
myocyte necrosis and replacement of contractile ﬁ  bers by 
connective tissue are likely to account for depressed cardiac 
performance, at least in advanced stages of diabetic cardio-
myopathy (Factor et al 1980). It appears that hypertrophy 
of myocardial cells and myocardial interstitial ﬁ  brosis may 
be present even in mild hyperglycemia in diabetes (Nunoda 
et al 1985).
Larger arteries
In animal models of type 2 diabetes it has been found that 
increased intimal proliferation and medial thickness as well 
as ECM deposition occur in vessels such as mesenteric arter-
ies and aorta (Song and Ergul 2006). Vascular remodeling 
and hypertrophy associated with augmented expression of 
dedifferentiation markers of vascular smooth muscle cells 
also occur in larger vessels like aorta (Vranes et al 1999). 
Fibronectin expression varied in different reports in large 
vessels (Fukuda et al 2005). Proteoglycans (PGs) such Vascular Health and Risk Management 2008:4(3) 577
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as versican, biglycan, and decorin have been involved in 
diabetic nephropathy pathogenesis (Schaefer et al 2001). 
PGs accumulate in developing atherosclerotic and restenotic 
lesions, and thus contribute to plaque burden and inﬂ  uence 
cellular and extracellular events associated with the patho-
genesis of vascular lesions, such as migration and prolifera-
tion, lipid metabolism and retention, and thrombosis (Shirk 
et al 2000; Edwards et al 2004; Nakashima et al 2007; Tran 
et al 2007).
Nonalcoholic fatty liver disease
Type 2 diabetic patients also have an increased risk for 
developing chronic liver disease. Nonalcoholic fatty liver 
disease (NAFLD) represents a spectrum of conditions char-
acterized histologically by excessive accumulation of hepatic 
fat in the absence of alcohol consumption. Obesity, type 2 
diabetes, dyslipidemia, and hypertension contribute to the 
risk for liver disease and to disease progression. Two main 
histological patterns of NAFLD are described: fatty liver 
alone and nonalcoholic steatohepatitis (NASH). NASH is 
an increasingly recognized cause of liver-related morbidity 
and mortality (Angulo 2002; Sanyal 2002; Charlton 2004), 
with about a quarter of patients progressing to serious liver 
sequelae, including end-stage liver disease and hepatocellular 
carcinoma (Bugianesi et al 2002; Ratziu et al 2002). Those at 
highest risk include patients with signiﬁ  cant hepatic necro-
inﬂ  ammation and ﬁ  brosis (Ratziu et al 2000; Sanyal 2002). 
Unlike other vascular beds, the normal hepatic sinusoids 
have no BM to become thickened. Sinusoidal (perisinusoidal) 
ﬁ  brosis with formation of BMs occurs in a variety of liver dis-
eases, including chronic viral hepatitis, alcoholic hepatitis and 
NASH. In those diseases, the ﬁ  brosis is a result of the activa-
tion of the hepatic stellate cells with a phenotypic transition to 
collagen-producing myoﬁ  broblasts. Activated hepatic stellate 
cells are involved in the ECM degradation and remodeling 
that occur with ﬁ  brogenesis (Sugimoto et al 2005).
Effects of diabetes on regulators 
of ECM turnover
Metabolic and hemodynamic induction 
of ﬁ  brosis by hyperglycemia
Chronic hyperglycemia is a main factor in the onset of 
microvascular diabetic complications in both type 1 and 
2 diabetes, as strict glycemic control reduces end-organ 
complication incidence and rate of progression (The Diabetes 
Control and Complications Trial Research Group 1993; UK 
Prospective Diabetes Study Group 1998). This pathogenesis is 
shown schematically in Figure 1. Speciﬁ  c biochemical pathways 
linking hyperglycemia to microvascular changes have been 
proposed: increased glucose ﬂ  ux through the polyol pathway 
(Greene et al 1987), nonenzymatic glycation of proteins 
(Brownlee et al 1988), glucose autooxidation, and oxidative 
stress (Hunt et al 1990), hyperglycemic pseudohypoxia 
Elevated blood glucose levels
(to diabetic range)
Diabetes end-organ complications
Insulin
deficiency
Initial insult(s)
(genetic and environmental)
Cell and tissue injury
Figure 1 The linear pathway leading from insulin deﬁ  ciency, through hyperglycemia to diabetes complications.Vascular Health and Risk Management 2008:4(3) 578
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(Williamson et al 1993), enhanced activation of protein kinase 
C isoforms (Lee et al 1989; DeRubertis and Craven 1994), and 
alteration in cell signaling pathways (Brownlee 2001; Sheetz 
et al 2002). As described in subsequent sections, experimental 
data support causative roles for hyperglycemia and these 
downstream biochemical pathways in causing alterations in 
ECM turn-over (Fukui et al 1992; Nahman et al 1992; Roy et al 
1994; Wahab et al 1996). Hyperglycemia can work through 
both metabolic and hemodynamic pathways to change growth 
factors and ECM turn-over. This is shown schematically in 
Figure 2.
Advanced glycation end-products (AGEs)
Hyperglycemia is responsible for the presence of high levels 
of nonenzymatically produced AGEs in patients with diabe-
tes (Goldin et al 2006). AGEs are able to stimulate directly 
the production of ECM. Nonenzymatic glycosylation of 
collagens produces cross-linkages and hence may produce 
physical alterations in the properties of the ECM. AGEs 
modiﬁ  cation of matrix proteins is able to disrupt matrix-
matrix and matrix-cell interactions, contributing to their 
proﬁ  brotic action. In addition, AGEs signiﬁ  cantly interact 
with the renin-angiotensin system. AGEs play important 
roles in cell signaling by interacting with speciﬁ  c receptors, 
receptor for advanced glycation end products (RAGE), that 
link to the activation of adhesion molecules, proinﬂ  amma-
tory cytokines and growth factors, thus contributing to the 
pathogenesis of diabetic complications (Mason et al 2003; 
McLennan et al 2004). AGEs have extracellular effects, 
such as protein cross-linking, that appear to inhibit ECM 
degradation and promote the expansion of the glomerular 
mesangial matrix and BM in diabetic kidney disease. Drugs 
that either inhibit the formation of AGE or break AGE-
induced cross-links have been shown to be renoprotective 
in experimental models of diabetic nephropathy (Forbes 
et al 2002).
The renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone system (RAAS) is an 
important contributor to the pathogenesis of diabetic micro- 
and macrovascular complications by inducing various tissue 
responses, such as vasoconstriction, inﬂ  ammation, oxidative 
stress, cell hypertrophy and proliferation, angiogenesis and 
ﬁ  brosis. RAAS effects can be locally generated in many 
organs (Paul et al 1993; Morgan et al 1994; Wagner et al 
1996; Engeli et al 1999; Bataller et al 2003).
Tissue insult Tissue injury
glucose  Metabolic Factors
-  AGEs
- Oxidant stress
- PKC/MAPK
           pathways
- polyol pathway
- hexosamine
          pathway
- fatty acid
(insulin resistance)
Tissue 
specific
effects 
Genetic
factors
Resolution
Inflammation
Cell infiltration
Cell loss
Cell proliferation
Fibrosis/scarring
Cell loss
Cell proliferation
Expansion of ECM
Neovascularisation
Figure 2 Schematic diagram indicating how hemodynamic and metabolic factors, and growth factors, can network to cause tissue damage. Inﬂ  ammation and ﬁ  brosis occur 
variably in tissue at different stages of diabetes complications.Vascular Health and Risk Management 2008:4(3) 579
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Angiotensin II (Ang II), the main physiological effector 
molecule of RAAS, mediates ﬁ  brosis by stimulating the 
synthesis of ECM components (Kagami et al 1994; Gomez-
Garre et al 1996; Brilla et al 1997) apoptosis/proliferation 
(Efrati et al 2007), inﬁ  ltration of inﬂ  ammatory cells, and the 
release of inﬂ  ammatory cytokines and growth factors such 
as transforming growth factor (TGF)-β1 (Wu et al 1997), 
monocyte chemoattractant protein (MCP)-1 (Ruiz-Ortega 
et al 1998), vascular endothelial growth factor (VEGF) 
(Otani et al 2000), platelet derived growth factor (PDGF) 
(Naftilan et al 1989), and connective tissue growth factor 
(CTGF) (Ruperez et al 2003a; Finckenberg et al 2003). Ang 
II is up-regulated under the diabetic conditions (Singh et al 
1999) and exerts its deleterious effects through the angiotensin 
type I receptor (AT1R). RAS blocking with either angiotensin 
converting enzyme inhibitors (ACEI) or angiotensin type 1 
receptor blockers (ARB) has clearly demonstrated positive 
outcomes on diabetic complications, with beneﬁ  ts beyond 
those derived from lowering blood pressure. Thus ACEI and/
or ARB treatment can slow the progression of diabetic renal 
disease (The EUCLID Study Group 1997; Heart Outcomes 
Prevention Evaluation Study Investigators 2000), decrease 
cardiovascular events (Heart Outcomes Prevention Evaluation 
Study Investigators 2000), may decrease retinopathy in T1DM 
(Chaturvedi et al 1998) and improves diastolic dysfunction 
in diabetic patients (Kawasaki et al 2007).
Another component of the RAAS, aldosterone, plays also 
a role in the development of hypertension, endothelial dys-
function, vascular structure damage, proteinuria, myocardial 
ﬁ  brosis, collagen synthesis (Cha et al 2005). Spironolactone, 
an aldosterone antagonist, associated to ACEI and/or ARB 
treatment may offer additional renoprotection in diabetic 
nephropathy (Sato et al 2003; Schjoedt et al 2006; van den 
Meiracker et al 2006).
Growth factors
Under normal circumstances ECM undergoes continuous 
synthesis and degradation and ECM turn-over is a requisite 
for normal structure and function of organs and tissues 
(Tyagi et al 1995). ECM turn-over is characterized by a 
balance between matrix formation and matrix degradation. 
Factors that regulate ECM formation include multiple forms 
of growth factor such as such as TGF-β (McClain et al 
1992; Kolm et al 1996; Riser et al 1998), CTGF (Twigg 
and Cooper 2004; Twigg et al 2001; McLennan et al 2004; 
Paradis et al 2001; Liu X et al 2007), and insulin-like growth 
factor I (IGF-I), ﬁ  broblast growth factor (FGF), epidermal 
growth factor (EGF) and PDGF, (Lembach 1976; Tseng et al 
1982; Dresow et al 1984; Roberts et al 1986; Qi et al 2005). 
Enzymes responsible for ECM degradation and remodeling 
include the matrix metalloproteinases (MMPs) (McLennan 
et al 1998, 2000; Death et al 2003), and serine proteases 
(Geiger et al 1988), as well as their respective tissue inhibi-
tors, the TIMPs (Nakamura et al 1994; Shankland et al 1996; 
Gomez et al 1997), and PAI-1 (Fisher et al 1997; McLennan 
et al 2000). These regulators of ECM will now be explored 
in detail in diabetic complications.
The important role of growth factors in the pathogenesis 
of diabetic long-term complications was suggested by their 
increased concentrations in target tissues (Yamamoto et al 
1993; Tikellis et al 2004; Roestenberg et al 2006; Umezono 
et al 2006). In diabetic nephropathy, IGF-I seems to be impli-
cated in the earlier stages of the disease, while TGF-β and 
CTGF are involved both in the early and later stages, being 
responsible, at least in part, for ECM accumulation (Park et al 
1997; Gilbert et al 1998; Riser et al 2000). VEGF and FGF 
play a pivotal role both in nonproliferative and proliferative 
retinopathy (Wells et al 1996; Mathews et al 1997).
Figure 3 indicates the main growth factors involved in 
diabetic complications, based on tissue levels measured 
in human and animal diabetes, and also on intervention 
studies mainly in animals. An excess of growth factor is 
implicated in tissues where ﬁ  brosis predominates, whereas 
a lack of growth factors occurs in diabetic neuropathy and 
wound healing.
TGF-β
TGF-β is generally accepted to be the main pro-ﬁ  brotic 
factor in diabetic nephropathy. Several lines of experimental 
and clinical evidence support a major role for TGF-β in 
development of glomerulosclerosis and interstitial ﬁ  brosis 
in diabetes. Diabetic environment up-regulated TGF-β1 
expression and bioactivity in glomerular mesangial cells 
and proximal tubule cells (Ziyadeh et al 1994, 1998; Sharma 
et al 1995). With the development of incipient diabetic 
nephropathy TGF-β mRNA increased in mesangial cells, 
podocytes and tubular epithelial cells. Progression to manifest 
diabetic nephropathy was associated with further increase 
in TGF-β mRNA, especially in the glomeruli (Wahab et al 
2005). The kidney of a diabetic patient actually elaborates 
TGF-β1 protein into the circulation whereas the kidney of 
a nondiabetic subject extracts TGF-β1 from the circulation 
(Sharma et al 1997). Inhibition of TGF-β1 with neutralizing 
antibodies prevented glomerular enlargement, and attenuated 
the excess matrix expression by reducing type IV collagen and 
ﬁ  bronectin mRNA (Sharma et al 1996; Ziyadeh et al 2000).Vascular Health and Risk Management 2008:4(3) 580
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Up-regulation of TGF-β protein was demonstrated in 
the myocardium of rodents with diabetic cardiomyopa-
thy. ARB treatment reduced its expression and decreased 
cardiac ﬁ  brosis (Westermann et al 2007). TGF-β is also 
involved in liver ﬁ  brosis (Roth et al 1998), by activating 
the hepatic stellate cells and inducing apoptosis of hepa-
tocytes in liver injury (Oberhammer et al 1992). However, 
due to its important anti-proliferative and anti-inﬂ  amma-
tory effects, TGF- β is not a suitable target for therapeutic 
intervention.
CTGF
CTGF is another prominent growth factor in the patho-
genesis of diabetic nephropathy. High glucose conditions, 
TGF-β, AGEs, RAS, TNF-α, mechanical strain or CTGF 
itself promote CTGF expression by mesangial cells (Wahab 
et al 1996; Murphy et al 1999; Riser et al 2000; Twigg et al 
2001, 2002a; Cooker et al 2007; Hughes et al 2007). CTGF 
can also be produced by podocytes (Roestenberg et al 2006), 
parietal epithelial cells (Umezono et al 2006) and proximal 
tubular cells (Wang et al 2001; Roestenberg et al 2006). 
In experimental type 1 and type 2 diabetes CTGF mRNA 
and protein was up-regulated in various organs: kidney, 
heart, liver, retina (Roestenberg et al 2006). Glomerular 
CTGF mRNA levels were found to be upregulated in dia-
betic patients with microalbuminuria as well as in overt 
nephropathy (Umezono et al 2006). In addition, CTGF 
mRNA levels were found to correlate with the degree of 
albuminuria (Adler et al 2001). We have recently found 
that renal tubular CTGF protein by renal biopsy at 5 years 
predicts albuminuria at 10 years, in a diabetic baboon model 
of type 1 diabetes (Thomson et al 2007). The role of CTGF 
in DN pathogenesis in both type 1 and type 2 diabetes has 
been conﬁ  rmed by a recent study showing that a CTGF 
antisense oligonucleotide may attenuate progression of 
nephropathy in mice (Guha et al 2007). CTGF overexpres-
sion in podocytes was critically involved in diabetes-related 
GBM thickening (Roestenberg et al 2006). However, a 
site-speciﬁ  c downregulation of CTGF accompanied by 
a reduced VEGF-A mRNA in glomeruli from diabetic 
patients can be evidenced in DN and is a result of podocyte 
loss (Baelde et al 2007).
Relative abundance of myocardial mRNA for CTGF 
compared with brain natriuretic peptide (BNP) was positively 
correlated with diastolic dysfunction, myocardial ﬁ  brosis 
area, and procollagen type 1 mRNA expression in a rat 
pressure overload cardiac hypertrophy model. Exogenous 
BNP prevented the production of CTGF in cardiac myocytes 
(Koitabashi et al 2007).
CTGF has been shown to be up-regulated in the retina of 
diabetic rats (Tikellis et al 2004). It appears that in diabetes 
CTGF expression shifts from microglia to microvascular 
pericytes (Kuiper et al 2004). CTGF was also expressed in 
endothelial cells and myoﬁ  broblast in PDR membranes, and 
in myoﬁ  broblast in proliferative vitreoretinal membranes 
(Abu El-Asrar et al 2007). CTGF is overexpressed in peri-
cytes in the human diabetic retina, irrespective of changes 
related to clinical DR like vascular leakage (Kuiper et al 
2004). Overexpression of CTGF in cultured human aortic 
smooth muscle cells, a cell type closely related to pericytes 
and mesangial cells, induced apoptosis by activating caspase 
3 (Hishikawa et al 1999).
Growth factor excess            Growth factor deficiency
• Diabetic nephropathy
- TGF-B, IGF-1, VEGF,
CTGF, PDGF, EGF, bFGF
• Diabetic retinopathy
- VEGF, IGF-1, CTGF,
angiopoetin-1, EGF
• Atherosclerosis
- TNF-A, TGF-B
•  Diabetic wounds
- PDGF, EGF, TGF-B,
VEGF, CTGF, bFGF
•  Diabetic neuropathy
-  IGF-1, NGF (nerve growth
factor)
•  Diabetic cardiomyopathy
- VEGF
Figure 3 The major growth factors implicated in diabetes complications. The prosclerotic ones involved in human diabetic ﬁ  brosis are currently thought to be TGF-β and 
CTGF.Vascular Health and Risk Management 2008:4(3) 581
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In ﬁ  brotic liver, CTGF mRNA and protein are produced 
by hepatocytes, ﬁ  broblasts, myoﬁ  broblasts, hepatic stellate 
cells (HSCs), endothelial cells, and bile duct epithelial cells 
(Rachfal et al 2003). Interestingly, whilst in HSCs CTGF was 
only marginally stimulated by TGF-β, in cultured hepatocytes 
it was strongly upregulated by TGF-β (Gressner et al 2007). 
CTGF could be reduced in liver by antisense RNA of CTGF 
recombinant or slicing through siRNA, which decreased 
activation of HSCs, prevented the upregulation of CTGF 
and TGF-beta1 gene expression and inhibited accumulation 
of connective tissue proteins in the liver (George et al 2007; 
Lu et al 2007).
Once induced, CTGF can up-regulate its own gene 
expression (Riser et al 2000; Twigg et al 2001; Wahab et al 
2001). It is also able to initiate changes in ECM composi-
tion: it increased expression of ﬁ  bronectin (Wahab et al 
2001; Ruperez et al 2003a; Weston et al 2003) and enhanced 
ﬁ  bronectin assembly into an insoluble matrix (Weston et al 
2003), increased in type IV (Zhou et al 2004), type III (Lam 
et al 2004) and type I collagen production (Gore-Hyer 
et al 2002), and up-regulated integrins on the cell surface, 
facilitating the deposition and assembly of ECM proteins 
(Weston et al 2003). Furthermore, CTGF caused induction of 
plasminogen activator inhibitor-1 (Wahab et al 2001), rear-
rangement of the actin cytoskeleton (Crean et al 2002) and 
an increase in TIMP-1 with subsequent decrease in matrix 
degradation (McLennan et al 2004). CTGF also exerted a 
strong chemotactic effect on peripheral blood mononuclear 
cells in vitro (Cicha et al 2005), which may then contribute 
to tissue inﬂ  ammation and late ﬁ  brosis (Frazier et al 1996).
CTGF has been described as a downstream media-
tor of TGF-β in the ﬁ  brotic process (Igarashi et al 1993; 
Grotendorst et al 1996; Duncan et al 1999; Weston et al 
2003; Kobayashi et al 2005). TGF-β1-induced effects can 
be blocked by CTGF antisense oligonucleotides (Duncan 
et al 1999; Abdel-Wahab et al 2002; Weston et al 2003). 
However, CTGF can also exert its pro-ﬁ  brotic effects via 
TGF-β1-independent pathways (Murphy et al 1999; Blom 
et al 2001; Twigg et al 2001; McLennan et al 2004; Chaqour 
et al 2006) as seen for induction of CTGF by AGEs which is 
TGF-β independent (Twigg et al 2001). Glucose-induced col-
lagen production was reduced by CTGF anti-sense nucleotide 
(Wahab et al 2001; Abdel-Wahab et al 2002; Ruperez et al 
2003a; Weston et al 2003; Guha et al 2007), ACEI or ARB 
(Ruiz-Ortega et al 1995; Wu et al 1997; Border et al 1998; 
Ruperez et al 2003b; Tsutsui et al 2007), or by treatment 
with an AGE inhibitor (Twigg et al 2002b; Candido et al 
2003). CTGF can interact with, and inﬂ  uence the signaling 
of IGF-I (Lam et al 2003), VEGF (Brigstock 2002), TGF-β 
(Grotendorst et al 1996) and bone morphogenic proteins 
(BMPs) (Abreu et al 2002). Moreover, CTGF can be cleaved 
by metalloproteases (MMPs) and other proteases (Hashimoto 
et al 2002).
PDGF-β
PDGF-β is involved in structural alterations at the glomerular 
level. It seems that high glucose induces an early activation 
of a PDGF loop that in turn causes an increase of TGF-β1 
gene expression, thus modulating both human mesangial 
cell proliferation and mesangial matrix production (Di Paolo 
et al 1996).
VEGF
VEGF appears to be another mediator for these early and late 
vascular changes. Neutralizing antibodies directed against 
VEGF blocked vascular permeability and blood ﬂ  ow changes 
induced by elevated tissue glucose and sorbitol levels in a 
dosage-dependent manner (de Vriese et al 2001). VEGF 
signaling affected GBM thickening, slit pore density, and 
nephrin quantity, all of which were associated with the extent 
of diabetic albuminuria. These effects could be blocked by a 
VEGF receptor inhibition (Sung et al 2006).
FGF
FGF is secreted by ﬁ  broblasts, macrophages and in particu-
lar endothelial cells (EC) in response to tissue injury and 
is important in promotion of neovascularization. Produced 
and stored in epiretinal membranes (Hueber et al 1996; 
Schneeberger et al 1997), FGF is a potent endothelial cell 
mitogen that has been proposed to play a role in prolifera-
tive diabetic retinopathy and other neovascular processes 
(Hanneken et al 1991).
Protease systems and their regulators
The MMP system
Metalloproteinases (MMPs) are a family of zinc-dependent 
enzymes with the combined ability to digest all ECM 
proteines: native and partially degraded ﬁ  brillar collagens, 
basement membrane collagens, proteoglycans, elastin, 
ﬁ  bronectin. The gelatinase (MMP-2 and MMP-9) are two 
proteinases primarily responsible for breaking down type 
IV collagen from the BMs. These are produced by multiple 
vascular cell types, such as pericytes, podocytes, vascular 
smooth muscles cells, renal mesangial cells, ﬁ  broblasts, mac-
rophages. The MMPs are synthesized as inactive zymogens 
with a pro-peptide domain that must be removed before the Vascular Health and Risk Management 2008:4(3) 582
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enzyme is active. Activation of MMPs can be induced by 
urokinase type (uPA) and tissue-type (tPA) plasminogen 
activators that cleave plasminogen into active plasmin. 
MMP-9, but not other MMPs, is able to upregulate biologi-
cally active proteins such as the proﬁ  brotic growth factor 
TGF-β (Rutschow et al 2006).
A major control point in the regulation of active enzyme 
is inhibition of the active form by their tissue family of inhibi-
tors. TIMPs comprise a family of four protease inhibitors 
(TIMP-1 to TIMP-4), which are expressed in a tissue speciﬁ  c 
pattern and regulate the function of MMPs either by inhibit-
ing active MMPs or by controlling their activation process. 
Overall, all MMPs are inhibited by TIMPs once they are 
activated, with most of the MMPs being inhibited by TIMP-1. 
The gelatinases (MMP-2 and MMP-9) can form complexes 
with TIMPs when the enzymes are in the latent form. The 
complex of latent MMP-2 (pro-MMP-2) with TIMP-2 serves 
to facilitate the activation of pro-MMP-2 at the cell surface 
by MT1-MMP (MMP-14), a membrane-anchored MMP. The 
role of the pro-MMP-9/TIMP-1 complex is unknown.
An imbalance between MMPs and TIMPs plays an 
important role in ECM modeling that favors tissue ﬁ  brosis. 
For example, the imbalance between the MMP-2 and TIMP-2, 
caused primarily by an increase in TIMP-2 activity, may 
contribute to the pathogenesis of diabetic nephropathy (Han 
et al 2006). Decreased MMP-2 expression and activity, and 
up-regulated MMP-9 protein were found in the myocardium 
of diabetic mice with STZ-induced DCM. These alterations 
were corrected by ARB treatment (Westermann et al 2007). 
Myoﬁ  broblasts and vascular endothelial cells in PDR mem-
branes expressed an increase in MMP-9 protein and activity 
(Abu El-Asrar et al 2007). ProMMP-9 and activated MMP-9 
levels were also signiﬁ  cantly increased in vitreous samples in 
PDR patients. In addition, TIMP-1 levels were signiﬁ  cantly 
increased in PDR patients. Activated MMP-9 levels in vitre-
ous samples of PDR patients with hemorrhage were higher 
than those in PDR patients without hemorrhage, suggesting 
that activated MMP-9 might be involved in hemorrhagic 
transformation in these patients (Descamps et al 2006).
The plasminogen system
Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) 
system is involved in ECM degradation. PAI-1 may promote 
ECM build-up by preventing plasmin and MMPs activation 
(McLennan et al 2000). PAI-1 can regulate TGF-beta expres-
sion by binding to uPAR and activating the extracellular-
regulated signal kinase (ERK)/MAPK pathway (Yang et al 
2007). PAI-1 plays a critical role in ECM remodeling in 
the kidney. Normal human kidneys do not express PAI-1 
but PAI-1 is overexpressed in pathologic conditions asso-
ciated with renal ﬁ  brosis including diabetic nephropathy 
(Paueksakon et al 2002; Hagiwara et al 2003). Reactive 
oxygen species mediate PAI-1 up-regulation in renal cells 
cultured under high glucose, hypoxia, and with TGF-beta1 
(Lee and Ha 2005). PAI-1 induced ECM deposition in dia-
betic kidney through increased ECM synthesis by TGF-beta1 
up-regulation as well as through decreased ECM degradation 
by suppression of plasmin and MMP-2 activity (Lee and Ha 
2005). Impaired ﬁ  brinolysis resulting from high plasma PAI-
1 can lead to excessive ﬁ  brin accumulation within vessels, 
resulting in atherothrombosis. Increased expression of PAI-1 
was found in the arterial wall in patients with type 2 diabetes 
(Pandolﬁ   et al 2001). This increased vascular expression of 
PAI-1 promotes neointima formation via accumulation of 
ﬁ  brin or ﬁ  brinogen as a result of inhibited clearance of plate-
let-ﬁ  brin thrombi. PAI-1, an acute phase protein, also has been 
involved in vascular inﬂ  ammation (Alessi et al 2004).
Figure 4 shows methods in diabetes by which pro-ﬁ  brotic 
growth factors may link with the protease and anti-protease 
systems to dysregulate ECM turnover and thus cause ECM 
accumulation.
Endothelin-1
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide, 
which can also exert pro-inﬂ  ammatory, mitogenic and pro-
ﬁ  brotic effects. Up-regulated by glucose, angiotensin II, 
TGF-β, ROS and PDGF in various renal cells (Zoja et al 
1991; Kohno et al 1992; Kohno et al 1993; Hughes et al 
1996; Hua et al 2001), retinal cells (Chakravarthy et al 1997; 
Park et al 2000; Yokota et al 2003) and cardiomyocytes, 
ET-1 has been linked with matrix accumulation in diabetic 
kidney (Ruiz-Ortega et al 1994; Hargrove et al 2000) and 
cardiomyocyte hypertrophy (Chen et al 2007), and with 
hemodynamic and histopathological abnormalities in diabetic 
retina (Bursell et al 1995; Takagi et al 1996; Chakrabarti et al 
1998). Neutralizing ET-antibodies and anti-sense oligonucle-
otides, as well as ET-receptor antagonist treatment reduced 
proteinuria and the production of ECM proteins in the kidney 
(Li et al 1999; Hocher et al 2001; Sugimoto et al 2002) and 
prevented myocardial and coronary dysfunction (Ding et al 
2006; Wolkart et al 2006) in experimental diabetes.
Markers of ﬁ  brosis in biological 
ﬂ  uids in diabetes
In order to assess accurately the morphological changes in 
the target organs and the extent to which the ﬁ  brotic changes Vascular Health and Risk Management 2008:4(3) 583
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affect their function, invasive studies (tissue biopsy) is 
commonly required. However, biopsy is not always feasible 
in human tissues and is associated with obvious risks. There-
fore it is highly desirable to potentially estimate the severity 
of organ ﬁ  brosis by measuring ECM factors in biological 
ﬂ  uids (peripheral blood or urine). Such markers, if proven 
they mirror the changes in speciﬁ  c organs structure and func-
tion, will allow a better monitoring of the disease. Moreover, 
if these markers levels show changes with treatment, they 
will be a useful tool to evaluate the therapeutic interventions. 
Thus the potential clinical value of the circulating or urinary 
levels of several ECM components and its regulators have 
been tested in diabetes and its complications.
ECM formation and degradation markers
Serum aminoterminal propeptide of type III (PIIINP) or 
type I (PINP) procollagen and carboxyterminal propeptide 
of type I procollagen (PICP) are released in a stoichiometric 
manner with collagen type III or I molecules during collagen 
biosynthesis, and therefore they are considered markers of 
the synthesis and deposition of type III and I collagen (Jensen 
et al 1990; Risteli et al 1995; Weber 1997). However, there 
is evidence that some of the PIIINP is also released during 
collagen degradation, because these propeptides are not 
completely cleaved during collagen synthesis (Fleischmajer 
et al 1985). Therefore, PIIINP could reﬂ  ect both synthesis 
and degradation of collagen.
Circulating levels of collagen have been suggested as 
indicators of diabetic complications. Elevated serum levels 
of both PIIINP and laminin were associated with the devel-
opment of diabetic microangiopathy (Okazaki et al 1988). 
Another study (Migdalis et al 1994) found elevated serum 
PIIINP levels in type 2 diabetic subjects with peripheral 
vascular disease and proposed that this reﬂ  ected an increase 
in collagen deposition in the large arteries that accompanies 
the development of macroangiopathy. Serum PIIINP was 
also increased in type 2 diabetic patients with nephropathy 
(Ishimura et al 1996).
PICP concentration did not differ between uncomplicated 
type 2 diabetic patients and controls, but it was increased 
in complicated diabetes and related to the progression of 
nephropathy (Inukai et al 2000). In contrast, other investigators 
Figure 4 One pathogenic pathway by which high glucose in diabetes and hypertension work through prosclerotic growth factors to dysregulate ECM turnover. Both TGF-β 
and CTGF have been shown to induce TIMP-1 and PAI-1, resulting in reduced MMP and plasmin activity. This paradigm best applies to diabetic renal disease.
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found decreased levels of serum PICP but increased PIIINP 
concentrations in subjects with proliferative retinopathy 
compared with those with no retinopathy (Arkkila et al 2001). 
Similarly, hypertensive type 2 diabetic patients had higher 
mean levels of PIIINP than controls, and lower mean levels 
of PINP and PICP (Alla et al 2006). No association between 
collagen markers and neuropathy was found (Arkkila et al 
2001).
ECM regulators as systemic 
ﬁ  brosis markers
In patients with type 1 diabetes plasma and urinary TGF-β1 
levels were signiﬁ  cantly higher than in controls. The effect 
of metabolic control on plasma TGF-β level is controversial 
(Azar et al 2000; Flores et al 2004; Thrailkill et al 2007). 
Increased TGF-β levels in both plama and urine were found 
especially in relation to diabetic nephropathy (Pfeiffer et al 
1996; Houlihan et al 2002). Urinary TGF-beta signiﬁ  cantly 
decreased with ACEI, ARB or thiazolinediones treatment, 
in parallel with a decrease in albuminuria (Matos et al 2005; 
Katavetin et al 2006; Song et al 2006; Woo et al 2006).
While it seems correlated with glycemic control 
(Kakizawa et al 2004), plasma VEGF concentration was not 
strongly correlated with risk factor status or microvascular 
disease in type 1 diabetes, nor was affected by ACE inhibi-
tion (Chaturvedi et al 2001). Urinary VEGF concentrations 
were signiﬁ  cantly higher in the diabetic groups, even at the 
normoalbuminuric stage, with further increase as diabetic 
nephropathy advanced (Kim et al 2004).
Diabetes status is associated with dysregulation in the 
circulating MMP/TIMP system even in the absence of 
complications. Thus, serum MMP-9 and TIMP-1 levels are 
increased in both type 1 (Maxwell et al 2001) and type 2 
diabetes (Tayebjee et al 2004), with no changes in MMP-2 
concentration. In contrast, in another study urine and plasma 
MMP-2 levels and plasma MMP-2 activity were all signiﬁ  -
cantly elevated in type 1 diabetic patients, with urine MMP-2 
correlated with higher HbA1c, longer duration of diabetes, 
evidence of renal hyperﬁ  ltration and the presence of micro-
albuminuria (Thrailkill et al 2007). Increased serum MMP-2 
and TIMP-1 concentrations, but no elevation of MMP-9 
levels, were also found in a cohort of diabetic patients with 
mild or no complications (Lee et al 2005).
Some therapies have been proven efﬁ  cient in reduction 
the plasma/serum MMPs and TIMP-1 levels in diabetic 
patients. Thiazolidinediones, which act via the PPARγ recep-
tor, reduced the increase in circulating levels of MMP-9 but 
had no effect on circulating MMP-2. Furthermore, reductions 
in MMP-9 levels were associated with decrease in other 
inﬂ  ammatory markers, such as C-reactive protein, PAI-1, 
IL-6, TNF-α and serum amyloid A (Haffner et al 2002; Marx 
et al 2003; Hanefeld et al 2007).
Circulating MMP-9 and TIMP-1 could also be reduced by 
lipid reduction therapy (plasma LDL apheresis) in diabetic 
patients with end-stage renal disease and arteriosclerosis 
obliterans (Nakamura et al 2003). Multifactorial cardiovas-
cular risk reduction therapy with intensive glucose control 
and statin therapy caused signiﬁ  cant reductions in circulating 
TIMP-1 levels (Tayebjee et al 2004). This effect was prob-
ably independent of blood pressure lowering, as the latter 
was relatively well controlled from the outset and did not 
fall signiﬁ  cantly.
Current evidence for clinical utility 
of markers of ﬁ  brosis in diabetes
Diabetic renal disease
Type IV collagen in the circulation or urine has been identi-
ﬁ  ed as a possible indicator of renal injuries, especially in 
early stages of diabetic nephropathy, in numerous, albeit 
relatively small studies (Watanabe et al 1991; Kotajima et al 
2000; Xu et al 2002; Tashiro et al 2004). Both serum and 
urinary type IV collagen increased in accordance with the 
clinical stage of the renal disease (Watanabe et al 1991, 2000; 
Xu et al 2002; Tashiro et al 2004). Serum carboxy-terminal 
propeptide type I procollagen (P1CP) levels may also reﬂ  ect 
the progression of diabetic nephropathy in patients with type 
2 diabetes (Inukai et al 2000). In type 1 diabetes, measure-
ment of syndecan-1 in serum has shown signiﬁ  cant increase 
even at the microalbuminuric stage compared to normoal-
buminuric patients (Svennevig et al 2006). TGF-β levels in 
serum were increased in patients with diabetic nephropathy 
(Sharma et al 1999) and decreased with ACEI (Ellis et al 
1998; Sharma et al 1999).
Urinary levels of collagen IV positively correlated with 
uPA, and that of ﬁ  bronectin negatively correlated with PAI-1 
in the diabetic patients with microalbuminuria (Woo et al 
2006). Urinary TGF-β was signiﬁ  cantly increased in type 2 
diabetic patients with micro- or macroalbuminuria. ACEI, 
ARB, and TZD signiﬁ  cantly reduced urinary excretion of 
TGF-β in these patients (Houlihan et al 2002; Praga et al 
2003; Matos et al 2005; Katavetin et al 2006; Song et al 
2006; Woo et al 2006).
Increasing evidence has emerged on circulating and uri-
nary CTGF as indicators of renal disease in diabetes. Elevated 
plasma CTGF concentrations have been found in diabetic 
nephropathy. CTGF levels in the circulation correlated with Vascular Health and Risk Management 2008:4(3) 585
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urinary albumin excretion, creatinine clearance, glycemic 
control and duration of diabetes (Roestenberg et al 2004). Of 
note, there was a wide overlap in plasma CTGF between nor-
moalbuminuric patients and those with diabetic nephropathy. 
Urinary concentrations of CTGF (U-CTGF) has been more 
extensively investigated than circulating CTGF, in diabetic 
renal disease (Gilbert et al 2003; Riser et al 2003; Nguyen 
et al 2006). U-CTGF was correlated with clinical markers 
of renal disease severity (urinary albumin excretion rate and 
glomerular ﬁ  ltration rate). Furthermore, the association of 
U-CTGF with diabetic nephropathy was comparable with that 
of the established risk factors: HbA1c and systemic blood 
pressure. Signiﬁ  cantly higher in patients with microalbumin-
uria or overt nephropathy, urinary CTGF excretion varied 
largely across the studies, from 1.6-fold (Nguyen et al 2006) 
to 6-fold (Riser et al 2003) and were 10–100-fold higher 
(Gilbert et al 2003) in diabetic nephropathy versus normo-
albuminuric subjects. Large overlaps in U-CTGF were also 
noted between patients and controls (Nguyen et al 2006). In 
patients with DN, U-CTGF correlated positively with urinary 
albumin excretion and negatively with GFR (Nguyen et al 
2006). It is unclear to what extent plasma CTGF levels con-
tribute to U-CTGF. CTGF and its fragments are predicted to 
be cleared from plasma by glomerular ﬁ  ltration.
Animal studies have shown increased CTGF mRNA in 
renal cortex in a very early phase of nephropathy, which 
paralleled an increase in plasma and U-CTGF (Roestenberg 
et al 2006). Local production of CTGF in the kidney, renal 
ﬁ  ltration of (elevated) plasma CTGF, together with tubular 
dysfunction and/or saturation of tubular reabsorption capac-
ity in proteinuric patients may all be involved in increased 
U-CTGF (Nguyen et al 2006). Interventional studies have 
shown that in type 1 diabetes with nephropathy, RAS block-
ade with ARB signiﬁ  cantly decreased U-CTGF concentra-
tion, and this reduction was associated with a slower rate of 
decline in GFR in a cohort of hypertensive type 1 diabetic 
patients with diabetic kidney disease (Andersen et al 2005). 
However, plasma CTGF remained unchanged throughout 
the study, suggesting that circulating CTGF is at least partly 
independent of U-CTGF and renal dysfunction.
In diabetic patients, plasma VEGF levels were found to be 
positively correlated with plasma urea and urinary ACR, and 
urinary VEGF was positively correlated with urinary ACR 
and creatinine. Urinary VEGF and serum creatinine were 
independently correlated with urinary ACR (Kim et al 2004). 
Urinary excretion of VEGF increased during the earlier stage 
of diabetic nephropathy and was signiﬁ  cantly correlated with 
urinary albumin excretion. This suggests that urinary VEGF 
might be used as a sensitive marker of diabetic nephropathy 
and for predicting disease progression (Kim et al 2004). In 
addition, another study implicated the potential of plasma 
VEGF as a DN marker (Baba et al 2004).
Dysregulations in circulating and urinary MMP/TIMP 
systems have been found in diabetic renal disease. Thus, 
increased levels of plasma MMP-9 have been shown in DN 
patients (Nakamura et al 2000; Zaoui et al 2000), and were 
signiﬁ  cantly reduced by ACEI treatment (Nakamura et al 
2000). Moreover, it seems that elevation in plasma MMP-9 
may precede the onset of microalbuminuria in type 2 dia-
betic patients (Ebihara et al 1998). Higher levels of MMP-9 
were also found in the urine of type 2 diabetic patients with 
macroalbuminuria (Tashiro et al 2004). Interestingly, uri-
nary MMP-9 levels were elevated not only in patients with 
diabetic renal disease but also in their ﬁ  rst-degree relatives 
when compared with healthy controls (Zaoui et al 2000). 
It has been suggested that increased urinary MMP-2 and 
MMP-9 activities, but not serum MMP levels, may be sensi-
tive markers of the extent of renal disease in type 1 diabetic 
patients (Tashiro et al 2004). Urine MMP-2 concentrations 
correlated with higher HbA1c levels, longer duration of 
disease, evidence of renal hyperﬁ  ltration, and the presence 
of microalbuminuria (Thrailkill et al 2007).
Another study has shown a signiﬁ  cant increase in urinary 
TIMP-1 in association with urinary albumin and the progress 
of glomerular diffuse lesions, while no correlation between 
serum TIMP-1 and urinary TIMP-1 was found (Kanauchi 
et al 1996). TIMP-1 was also increased in the urine in a 
group of nondiabetic patients with chronic renal disease and 
was correlated with progressive reduction in renal function, 
but not with proteinuria (Horstrup et al 2002). In an animal 
model urinary protein excretion showed a signiﬁ  cant posi-
tive correlation with glomerular and tubular TIMP-2 protein, 
and a negative correlation with MMP-2 expression (Han 
et al 2006).
Diabetic retinopathy
Increased synthesis of type III collagen (serum PIIINP), 
reﬂ  ecting deposition of matrix and BM connective tissue, 
has been reported in patients with DPR (Arkkila et al 2001). 
While some investigators have found no signiﬁ  cant differ-
ences of serum carboxy-terminal propeptide of human type 
I procollagen (PICP) across the differing severity of diabetic 
retinopathy in type 2 diabetic patients (Inukai et al 2000), oth-
ers have actually observed progressively decreased levels of 
serum PICP, which can result in weakened vascular integrity 
in subjects with retinopathy (Arkkila et al 2001).Vascular Health and Risk Management 2008:4(3) 586
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Diabetic retinopathy is associated with increased 
concentrations of type IV collagen in serum (Yano et al 1998; 
Kotajima et al 2001). Although in the vitreous the NH2-
terminal CTGF fragment content was increased in patients 
with active PDR, suggesting that it may play a pathogenic 
role or may represent a surrogate marker of CTGF activity in 
DR (Hinton et al 2004), the elevated level of plasma CTGF 
found in the circulation in patients with DR compared with 
patients without DR seems likely to be due to associated 
nephropathy rather than to the retinopathy itself (Roestenberg 
et al 2004). In addition, no changes in urinary CTGF were 
noted in DR (Nguyen et al 2006).
Increased plasma levels of VEGF and Ang II were found 
in diabetic patients, with the highest VEGF and Ang II 
levels being seen among patients with pre-proliferative and 
proliferative retinopathy (Lip et al 2004). The clinical utility 
of plasma VEGF levels after photocoagulation has yielded 
contradictory results (Lip et al 2000; Lip et al 2004).
Diabetic patients with retinopathy also displayed 
elevated systemic values of MMP-9 and MMP-9/TIMP-1 
ratio when compared with patients without retinopathy. 
Logistic regression analysis identiﬁ  ed diabetes duration 
ﬁ  rstly, and MMP-9 serum levels secondly as signiﬁ  cant 
and independent variables associated with the existence 
of retinopathy in type 1 diabetic patients who were free 
of other overt vascular complications (Jacqueminet et al 
2006).
Diabetic cardiomyopathy, heart failure
A strong correlation has been reported between myocardial 
collagen content and serum concentration of PICP in systemic 
hypertension (Querejeta et al 2000). Moreover, serum PICP 
has been found to be secreted by the heart via the coronary 
sinus in patients with hypertensive heart disease (Querejeta 
et al 2004). Thus, even if these markers could be released 
from various other tissues in diabetes or hypertension, the 
measurement of serum collagen degradation products may 
offer a reasonable evaluation of myocardial ECM changes 
in diabetes. In a highly selected group of uncomplicated type 
2 diabetic patients, parameters of myocardial function were 
positively correlated with glutathione peroxidase and serum 
PICP, but not with levels of angiotensin II, aldosterone or 
endothelin-1 (Gonzalez-Vilchez et al 2005). Serum pro-
peptide of procollagen type I (PIP) appears an independent 
predictor of new heart failure episodes, readmission and death 
and a single serum measurement of PIP may have prognostic 
value in patients presenting with decompensated heart failure 
(Ruiz-Ruiz et al 2007).
In hypertensive subjects, plasma TIMP-1 levels were 
increased and associated with LVH and LV diastolic 
impairment in some (Laviades et al 1998; Lindsay et al 
2002; Timms et al 2002) but not all studies (Li-Saw-Hee 
et al 2000). Treatment of hypertension with ACEI has been 
shown to decrease TIMP-1 levels (Laviades et al 1998). 
Previous studies of small samples of patients with heart 
failure or LV dilatation have yielded inconsistent results, 
with both increased and decreased levels of myocardial or 
serum TIMP-1 being reported. (Li et al 1998; Schwartzkopff 
et al 2002). The Framingham Heart Study (Sundstrom et al 
2004) has shown that plasma total TIMP-1 is directly related 
to major CVD risk factors and to echocardiographic indices 
of LVH, and inversely to systolic dysfunction.
It has also been suggested that elevated TIMP-1 might 
be a useful noninvasive marker of left ventricular diastolic 
dysfunction and fibrosis (Lindsay et al 2002). Serum 
TIMP-1 concentrations over 500 ng/ml showed good speci-
ﬁ  city and positive predictive value for detecting diastolic 
dysfunction among untreated patients with hypertension 
(Lindsay et al 2002). In an asymptomatic population with 
either diabetes or hypertension, but with no evidence of LV 
hypertrophy, plasma TIMP-1 negatively correlated with 
e’ (early diastolic velocity at the annulus). This suggests 
that the higher circulating levels of TIMP-1 may reﬂ  ect 
structural changes within the heart that result in diastolic 
dysfunction. The correlation was however stronger among 
the hypertensive patients when compared with the diabetic 
group, suggesting again that systemic hypertension may 
mainly mediate the TIMP-1 and diastolic dysfunction link 
(Tayebjee et al 2005a).
Increased serum levels of AGEs were associated with 
heart stiffness in patients with type 1 diabetes, possibly 
mediated by the cross-linking properties of AGEs (Berg 
et al 1999).
Atherosclerosis and arteriosclerosis
Plasma plasminogen activator inhibitor (PAI)-1, a potent 
inhibitor of ﬁ  brinolysis, was elevated in a number of clinical 
situations that are associated with high incidence of car-
diovascular disease (CVD) (obesity, hypertension, type 2 
diabetes) (Hoekstra et al 2004).
Serum 7S-collagen levels in diabetic patients with essen-
tial hypertension were signiﬁ  cantly higher than in normal 
subjects, and signiﬁ  cantly correlated with systolic blood 
pressure. Thus it has been suggested that the metabolic 
alteration of basement membrane occurring in patients with 
diabetes mellitus may worsen in the presence of high systolic Vascular Health and Risk Management 2008:4(3) 587
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blood pressure (Yano et al 1997). In hypertensive type 2 
diabetic patients there were also noted an imbalance between 
serum MMP-1 which was decreased, and its tissue inhibitor, 
TIMP-1 which was not signiﬁ  cantly changed compared to 
controls (Alla et al 2006).
Diabetic patients with acute coronary syndromes showed 
increased plasma levels of MMP-9, TIMP-1, and TIMP-2 
(Derosa et al 2007). A high percent of patients with coronary 
artery disease (CAD) or acute coronary syndromes (ACS) had 
elevated urine values of MMP-9 and TIMP-1 suggesting that 
these variables might be a useful marker of atherosclerotic 
disease (Fitzsimmons et al 2006). Plasma levels of MMP-9, 
TIMP-2, but not TIMP-1 were high in patients with stable 
CAD compared with healthy controls. However, no corre-
lation with severity of CAD or collateralization was found 
(Tayebjee et al 2005b).
In patients with premature coronary atherosclerosis, the 
levels of plasma MMP-9 and TIMP-1 were signiﬁ  cantly 
higher, and the levels of MMP-2, MMP-3, and TIMP-2 were 
signiﬁ  cantly lower than those of controls, with signiﬁ  cant 
positive correlation between plasma MMP-9 levels and low-
density lipoprotein (LDL)-cholesterol levels, and signiﬁ  cant 
negative correlation between plasma MMP-9 levels and 
high-density lipoprotein (HDL)-cholesterol levels. TIMP-2 
levels were negatively correlated with total cholesterol and 
LDL-cholesterol levels (Noji et al 2001).
In patients with CAD the low TGF-β group had a 
signiﬁ  cantly poor prognosis in terms of survival without 
cardiovascular events and survival without coronary 
interventions as compared with the high TGF-β group, while 
other prognoses were comparable between the two groups. 
These results suggest that lower plasma concentrations 
of TGF-β may have an adverse prognostic signiﬁ  cance in 
patients with CAD (Tashiro et al 2002). In another study, 
plasma TGF-β levels were signiﬁ  cantly lower in patients with 
ischemic heart disease than they were in controls (Tashiro 
et al 1997).
Liver ﬁ  brosis
The serum glyceraldehyde-derived AGEs level may be a 
useful biomarker for discriminating NASH from simple 
steatosis. Moreover, it correlated with adiponectin (Hyogo 
et al 2007). Serum hyaluronic acid could identify NAFLD 
in patients with severe ﬁ  brosis in some (Sakugawa et al 
2005; Kaneda et al 2006) , but not all studies (Yoneda et al 
2007). Type IV collagen 7 s domain and type IV collagen 7s 
domain concentrations in the circulation have been identi-
ﬁ  ed as potential markers in differentiating between NASH 
and NAFLD (Sakugawa et al 2005), and between advanced 
and mild liver ﬁ  brosis (Yoneda et al 2007). Serum levels 
of endothelin-1 (ET-1), an inﬂ  ammatory and marker of 
increased endothelial tone, also showed a signiﬁ  cant positive 
correlation with liver ﬁ  brosis severity in patients with NASH 
(Degertekin et al 2007).
TIMP-1 and MMP-1 levels in serum or peripheral blood 
mononuclear cells (PBMCs) seem to have some value in 
assessing liver ﬁ  brosis. The combination of serum PDGF-BB, 
TIMP-1 mRNA and TIMP-1mRNA/MMP-1mRNA ratio in 
PBMCs was suggested as an efﬁ  cient test in screening for 
the presence of liver ﬁ  brosis (Zhang et al 2003).
Research required in circulating 
and urinary markers of ﬁ  brosis 
in diabetes
Important issues appear when interpreting levels of the 
ECM markers and their regulators in blood or urine from 
diabetic patients. First, it is not yet clear whether the assess-
ment of these markers in biological ﬂ  uids provide clinically 
valuable information of the ﬁ  brosis process in the affected 
organs and whether tissue levels are reﬂ  ected accurately in 
blood or urine. Factors such as the relative contribution of a 
tissue to a particular circulating marker and also the rate of 
clearance of the marker from the circulation and its depen-
dence on renal function can have signiﬁ  cant effects on its 
level. Nevertheless, the fact that different therapies impact 
upon their levels indicates that they may be involved in the 
pathological process.
A second issue is the presence of conditions that com-
monly co-exist with diabetes, such as hypertension and/or 
dyslipidemia, which could also influence the levels of 
circulating/urinary markers of ﬁ  brosis. The differentiation 
between the contribution of diabetes and other co-morbidities 
to the total level of ECM markers in blood/urine could there-
fore be difﬁ  cult to assess.
Figure 5 summarizes the main ﬁ  ndings of circulating and 
urinary markers and their regulators and their potential value 
in diabetes complications. At this time, Type IV collagen 
and CTGF in plasma and urine hold promise in diabetic 
renal disease, MMP-9 has promise in acute coronary syn-
dromes as does TIMP-1 and also in myocardial dysfunction. 
Longitudinal and large studies in appropriate populations of 
people with diabetes, will be needed to further investigate the 
possible clinical value of these and other ECM components 
and ECM regulators as makers for incipient or progressive 
diabetes complications. Ideally, such markers in their natu-
ral history and after therapy, would show predictive value Vascular Health and Risk Management 2008:4(3) 588
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independent of other common clinical variables such as 
hypertension, degree of glycemic control, and microalbumin-
uria. It is envisaged that clinically veriﬁ  ed algorithms will be 
generated where automated plasma or urine measures will 
aid in the calculation of risk of tissue ﬁ  brosis, and related 
organ dysfunction. It may be that other, tissue speciﬁ  c mea-
sures such as BNP for the heart or liver function tests for 
liver ﬁ  brosis, will be useful in combination with such ECM 
markers. Urinary measures do appear to often be indepen-
dent of circulating levels, although whether such measures 
have advantage over albuminuria and estimated GFR levels, 
remains to be determined.
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